Show simple item record

dc.contributor.authorCalvo Río, Vanesaes_ES
dc.contributor.authorBlanco Alonso, Ricardoes_ES
dc.contributor.authorSantos Gómez, Montserrates_ES
dc.contributor.authorRubio Romero, Estebanes_ES
dc.contributor.authorCordero Coma, Migueles_ES
dc.contributor.authorGallego Flores, Adelaes_ES
dc.contributor.authorVeroz, Raúles_ES
dc.contributor.authorTorre, Ignacioes_ES
dc.contributor.authorHernández, Félix Franciscoes_ES
dc.contributor.authorAtanes, Antonioes_ES
dc.contributor.authorLoricera García, Javieres_ES
dc.contributor.authorGonzález Vela, María del Carmen es_ES
dc.contributor.authorPalmou, Nataliaes_ES
dc.contributor.authorHernández Hernández, José Luis es_ES
dc.contributor.authorGonzález-Gay Mantecón, Miguel Ángel es_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2017-08-10T07:30:11Z
dc.date.available2017-08-10T07:30:11Z
dc.date.issued2016-03-04es_ES
dc.identifier.issn0049-0172es_ES
dc.identifier.issn1532-866Xes_ES
dc.identifier.urihttp://hdl.handle.net/10902/11559
dc.description.abstractObjective: To assess the efficacy of golimumab (GLM) in refractory uveitis associated to spondyloarthritis (SpA). Methods: Multicenter study of SpA-related uveitis refractory to at least one immunosuppressive drug. The main outcome variables were degree of anterior and posterior chamber inflammation, visual acuity, and macular thickness. Results: Fifteen patients (13 men/2 women; 18 affected eyes; mean age 39±6 years) were evaluated. The underlying SpA subtypes were ankylosing spondylitis (n=8), psoriatic arthritis (n=6) and non-radiographic axial SpA (n=1). The ocular involvement patterns were recurrent anterior uveitis in 8 patients and chronic anterior uveitis in 7. Before GLM they have received methotrexate (n=13), sulfasalazine (n=6), pulses of methylprednisolone (n=4), azathioprine (n=3), leflunomide (n=2) and cyclosporine (n=1). Ten of them had also been treated with TNF-? blockers; etanercept (n=7), adalimumab (n=7), infliximab (n=6), and certolizumab (n=1). GLM was given at the standard dose (50 mg/sc/monthly) as monotherapy (n=7) or in combination with conventional immunosuppressive drugs (n=8), mainly methotrexate. Most patients had rapid and progressive improvement of intraocular inflammation parameters. The median number of cells in the anterior chamber at 2 years (0 [0-0]) was significantly reduced compared to baseline findings (1 [0-3]); p=0.04). The mean best corrected visual acuity value also improved (0.84±0.3 at 2 years versus 0.62±0.3 at baseline; p=0.03). Only minor side effects were observed after a mean follow-up of 23±7 months. Conclusions: Our results indicate that GLM may be a useful therapeutic option in refractory SpA-related uveitis.es_ES
dc.format.extent27 p.es_ES
dc.language.isoenges_ES
dc.publisherW.B. Saunderses_ES
dc.rights© 2016, Elsevier. Licensed under the Creative Commons Reconocimiento-NoComercial-SinObraDerivadaes_ES
dc.sourceSeminars in Arthritis and Rheumatism Volume 46, Issue 1, August 2016, Pages 95-101es_ES
dc.titleGolimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.identifier.DOI10.1016/j.semarthrit.2016.03.002es_ES
dc.type.versionacceptedVersiones_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record